Evidence map›Paper›PMID 35031902›Full record

ArticleBreast cancer research and treatment2022

Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.

Ana Carolina Pavanelli, Flavia Rotea Mangone, Piriya Yoganathan, Simone Aparecida Bessa, Suely Nonogaki, Cynthia A B de Toledo Osório, Victor Piana de Andrade, Iberê Cauduro Soares, Evandro Sobrosa de Mello, Lois M Mulligan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Ana Carolina PavanelliDiscipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, 01246-903, Brazil.
Flavia Rotea MangoneDiscipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, 01246-903, Brazil.
Piriya YoganathanDepartment of Pathology and Molecular Medicine, Cancer Research Institute, Queen's University Kingston, 18 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Simone Aparecida BessaDiscipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, 01246-903, Brazil.
Suely NonogakiDepartment of Pathological Anatomy, A. C. Camargo Cancer Center, São Paulo, 01509-020, Brazil.
Cynthia A B de Toledo OsórioDepartment of Pathological Anatomy, A. C. Camargo Cancer Center, São Paulo, 01509-020, Brazil.
Victor Piana de AndradeDepartment of Pathological Anatomy, A. C. Camargo Cancer Center, São Paulo, 01509-020, Brazil.
Iberê Cauduro SoaresDepartment of Pathology, Cancer Institute of Sao Paulo, Hospital das Clinicas, Faculty of Medicine, University of São Paulo, HCFMUSP, São Paulo, 01246-903, Brazil.
Evandro Sobrosa de MelloDepartment of Pathology, Cancer Institute of Sao Paulo, Hospital das Clinicas, Faculty of Medicine, University of São Paulo, HCFMUSP, São Paulo, 01246-903, Brazil.
Lois M MulliganDepartment of Pathology and Molecular Medicine, Cancer Research Institute, Queen's University Kingston, 18 Stuart Street, Kingston, ON, K7L 3N6, Canada.
Maria Aparecida NagaiDiscipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, 01246-903, Brazil. nagai@usp.br.ORCID http://orcid.org/0000-0002-0728-4937
Universidade de São Paulo · BRAC Camargo Hospital · BRQueen's University · CA

Funding

conselho nacional de desenvolvimento científico e tecnológico 309524/2017-2fundação de amparo à pesquisa do estado de são paulo 2019/05252-4
6 · The paper itself

Abstract

purposeBreast cancer (BC) is considered a heterogeneous disease composed of distinct subtypes with diverse clinical outcomes. Luminal subtype tumors have the best prognosis, and patients benefit from endocrine therapy. However, resistance to endocrine therapies in BC is an obstacle to successful treatment, and novel biomarkers are needed to understand and overcome this mechanism. The RET, BCAR1, and BCAR3 genes may be associated with BC progression and endocrine resistance.

methodsAiming to evaluate the expression profile and prognostic value of RET, BCAR1, and BCAR3, we performed immunohistochemistry on tissue microarrays (TMAs) containing a cohort of 361 Luminal subtype BC.

resultsLow expression levels of these three proteins were predominantly observed. BCAR1 expression was correlated with nuclear grade (p = 0.057), and BCAR3 expression was correlated with lymph node status (p = 0.011) and response to hormonal therapy (p = 0.021). Further, low expression of either BCAR1 or BCAR3 was significantly associated with poor prognosis (p = 0.005; p = 0.042). Pairwise analysis showed that patients with tumors with low BCAR1/low BCAR3 expression had a poorer overall survival (p = 0.013), and the low BCAR3 expression had the worst prognosis with RET high expression stratifying these patients into two different groups. Regarding the response to hormonal therapy, non-responder patients presented lower expression of RET in comparison to the responder group (p = 0.035). Additionally, the low BCAR1 expression patients had poorer outcomes than BCAR1 high (p = 0.015).

conclusionOur findings suggest RET, BCAR1, and BCAR3 as potential candidate markers for endocrine therapy resistance in Luminal BC.

Indexed as

Breast NeoplasmsAdaptor Proteins, Signal TransducingBiomarkers, TumorCrk-Associated Substrate ProteinFemaleGuanine Nucleotide Exchange FactorsHumansImmunohistochemistryPrognosisProto-Oncogene Proteins c-retAdaptor Proteins, Signal TransducingBCAR1 protein, humanBCAR3 protein, humanBiomarkers, TumorCrk-Associated Substrate ProteinGuanine Nucleotide Exchange FactorsProto-Oncogene Proteins c-retRET protein, humanBCAR1BCAR3Breast cancerEndocrine resistanceRET

Identifiers

PMID35031902
OpenAlexW4205726578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.